Plain-English translation of NCT06970119 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called in men with advanced prostate cancer that has progressed despite previous treatments. INR102 is a radioactive injection designed to find and target cancer cells in the body. Researchers want to understand how safe this treatment is, how well it works, and the right dose to use.
Men with advanced castration-resistant prostate cancer often run out of effective treatment options after standard therapies stop working. This medication offers a new approach by using radioactivity to directly target cancer cells, which may help patients whose cancer has become resistant to other drugs.
You likely qualify if…
You likely don't qualify if…
You will visit a research clinic to receive at a dose determined safe in earlier parts of the study. The team will monitor you closely with blood tests and imaging scans to track how your body responds and whether the cancer responds to treatment. You will have follow-up visits to check for side effects and measure how well the medication is working, with the study lasting several months or longer depending on your response.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China